Envoy Medical, Inc. (COCH)
| Market Cap | 54.81M +94.4% |
| Revenue (ttm) | 207,000 -6.8% |
| Net Income | -28.46M |
| EPS | -0.51 |
| Shares Out | 77.19M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 17,122 |
| Open | 0.6900 |
| Previous Close | 0.6903 |
| Day's Range | 0.6900 - 0.7199 |
| 52-Week Range | 0.3625 - 1.8900 |
| Beta | 1.89 |
| Analysts | Strong Buy |
| Price Target | 2.00 (+181.69%) |
| Earnings Date | Aug 10, 2026 |
About COCH
Envoy Medical, Inc., a hearing health company, provides medical technologies across the hearing loss spectrum. The company’s medical technologies are designed to shift the paradigm within the hearing industry and bring providers and patients the hearing devices desire. It offers personal sound amplification devices; hearing aids; Esteem fully implanted active middle ear implants; auditory osseointegrated implants; and Acclaim cochlear implants. The company was formerly known as Envoy Medical Corporation and changed its name to Envoy Medical, In... [Read more]
Financial Performance
In 2025, Envoy Medical's revenue was $241,000, an increase of 7.11% compared to the previous year's $225,000. Losses were -$28.66 million, 2.46% more than in 2024.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for COCH stock is "Strong Buy." The 12-month stock price target is $2.0, which is an increase of 181.69% from the latest price.
News
Envoy Medical to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14th-16th
White Bear Lake, Minnesota--(Newsfile Corp. - September 2, 2026) - Envoy Medical ® Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted hea...
Envoy Medical Proxy statement: Proxy filing
Envoy Medical filed a proxy statement on September 2, 2026, providing details for shareholder voting and corporate governance matters.
Envoy Medical Proxy statement: Proxy filing
Envoy Medical filed a proxy statement on August 31, 2026, providing details for shareholder voting and corporate governance matters.
Envoy Medical price target lowered to $2 from $2.50 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Envoy Medical (COCH) to $2 from $2.50 and keeps a Buy rating on the shares. The firm cites a projected higher number…
Envoy Medical Proxy statement: Proxy filing
Envoy Medical filed a proxy statement on August 19, 2026, providing details for shareholder voting and corporate governance matters.
Envoy Medical Reports Second Quarter 2026 Results and Achieves Key Regulatory and Clinical Milestones
Submitted First Module of Modular PMA Application to FDA Subsequent to Quarter End, the Company Reported Positive 12-Month Stage 1 Data Showing Continued Improvement in Speech Perception White Bear La...
Envoy Medical Quarterly report: Q2 2026
Envoy Medical has published its Q2 2026 quarterly earnings report on August 10, 2026.
Envoy Medical Earnings release: Q2 2026
Envoy Medical released its Q2 2026 earnings on August 10, 2026, summarizing the period's financial results.
Envoy Medical Slides: Investor presentation
Envoy Medical has posted slides in relation to its latest quarterly earnings report, which was published on August 5, 2026.
Envoy Medical initiated with a Buy at Lucid Capital
Lucid Capital analyst Alex Nowak initiated coverage of Envoy Medical (COCH) with a Buy rating and $2 price target The firm says Envoy is redefining the hearing health industry with…
Envoy Medical Surpasses Three-Month Visit Milestone for All 56 Patients in Pivotal Clinical Trial
White Bear Lake, Minnesota--(Newsfile Corp. - July 21, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing soluti...
Envoy Medical Reports Positive 12-Month Data Showing Continued Improvement in Speech Perception in Study of First-of-Its-Kind Fully Implanted Cochlear Implant
Mean CNC word recognition scores for Stage 1 cohort improved to 53.2% at 12 months from 15.2% pre-implantation, a 38.0 percentage point gain that continued to build on the 24.0 percentage point improv...
Envoy Medical Submits First Module of Modular Premarket Approval Application to the U.S. Food and Drug Administration for Breakthrough-Designated Device
Modular Regulatory Strategy Creates Defined Milestone Cadence, Enables Earlier FDA Engagement, and Supports Targeted Final Clinical Module Submission Planned for Q2 2027 White Bear Lake, Minnesota--(N...
Envoy Medical Transcript: Life Sciences Virtual Investor Forum
A fully implanted cochlear implant with unique sensor and battery design targets a large, underserved U.S. market. Clinical trials are fully enrolled, with FDA submission planned for next year and potential approval by late 2027. Strong IP, first-mover status, and strategic board additions position the company for significant disruption.
Envoy Medical Terminates At-the-Market (ATM) Equity Facility
Termination Reflects Company's Confidence in Current Capital Position White Bear Lake, Minnesota--(Newsfile Corp. - June 25, 2026) - Envoy Medical®, Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing he...
Envoy Medical Slides: Investor presentation
Envoy Medical has posted slides in relation to its latest quarterly earnings report, which was published on June 25, 2026.
Envoy Medical to Present at Investor Conferences on June 25th
White Bear Lake, Minnesota--(Newsfile Corp. - June 18, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing soluti...
Envoy Medical Transcript: Planet MicroCap Las Vegas 2026
A fully implanted cochlear implant with unique sensor and chest battery aims to disrupt a large, underpenetrated market, offering invisible, 24/7 hearing and compatibility with wearables. Clinical trials are complete, FDA submission is planned for next year, and insurance coverage is in place.
Envoy Medical to Present at Planet MicroCap Conference Las Vegas on June 16th-18th
White Bear Lake, Minnesota--(Newsfile Corp. - June 4, 2026) - Envoy Medical® Inc. (NASDAQ: COCH), a hearing health company pioneering fully implanted hearing solutions, today announced that Brent Luca...
Envoy Medical signs multi-part series with New to The Street
Envoy Medical (COCH) has signed a multi-part national media series with New to The Street. The campaign is designed to increase awareness among investors, and the broader marketplace about the…
Envoy Medical Slides: Investor presentation
Envoy Medical has posted slides in relation to its latest quarterly earnings report, which was published on June 1, 2026.
Envoy Medical Announces New Patents Expanding Intellectual Property Portfolio in Fully Implanted Hearing Technology
Australian and European Patent Offices Grant the Company Four Patents Relating to Key Innovations in Implantable System Design, Signal Analysis, and Battery Recharge Safety White Bear Lake, Minnesota-...
Envoy Medical Reports Landmark Accomplishments, Advancing Toward FDA Approval of First-of-Its-Kind Fully Implanted Cochlear Implant
Company Completes Historic Trial Enrollment, Secures Transformational Financing, and Sees Promising Early Clinical Data Presented at Industry Conferences White Bear Lake, Minnesota--(Newsfile Corp. - ...
Envoy Medical Earnings release: Q1 2026
Envoy Medical released its Q1 2026 earnings on May 11, 2026, summarizing the period's financial results.
Envoy Medical Quarterly report: Q1 2026
Envoy Medical has published its Q1 2026 quarterly earnings report on May 11, 2026.